



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

TADALAFIL

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TADALAFIL	CIALIS		20736 99409	GPI-14 (40304080000305) (40304080000302)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of Benign Prostatic Hyperplasia (BPH)?

If yes, continue to #2.

If no, continue to #3.

2. Has the patient tried or had a contraindication to at least **TWO** preferred formulary agents, including **ONE** agent from **EACH** of the following classes?

- 5-alpha-reductase inhibitors: (e.g., finasteride or dutasteride)
- Alpha blockers: (e.g., doxazosin, terazosin, tamsulosin, or alfuzosin)

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **Cialis 2.5mg OR 5mg: #30 per 30 days.**

If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

3. Does the patient have a diagnosis of erectile dysfunction?

If yes, continue to #4.

If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

4. Is erectile dysfunction a covered benefit?

If yes, continue to #5.

If no, guideline does not apply.

5. Has the patient tried generic sildenafil (Viagra)?

If yes, **approve for 12 months by GPID or GPI-14 for the requested strength as follows:**

- **Cialis 2.5mg OR 5mg: #30 per 30 days.**

If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

TADALAFIL

GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TADALAFIL (Cialis)** requires the following rule(s) be met for approval:

- A. You have benign prostatic hyperplasia (BPH: your prostate is too big causing difficulty urinating) OR erectile dysfunction (difficulty getting/keeping an erection)
- B. **If you have benign prostatic hyperplasia (BPH), approval also requires:**
 - 1. You previously tried at least two preferred formulary alternatives, including one medication from each of the following classes:
 - a. 5-alpha-reductase inhibitors: (such as finasteride or dutasteride)
 - b. Alpha blockers: (such as doxazosin, terazosin, tamsulosin, or alfuzosin)
- C. **If you have erectile dysfunction, approval also requires:**
 - 1. You have previously tried generic sildenafil (Viagra)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Cialis.

REFERENCES

- Cialis [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company. February 2018.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 09/07/20

Created: 11/14

Client Approval: 08/20

P&T Approval: 01/18